Depression, Anxiety, Knowledge, Beliefs About Medication and Quality of Life Among Newly Anticoagulated Atrial Fibrillation Patients

H.H. Zulkiflly; Professor Gregory Lip; Deirdre A. Lane

doi:10.1016/j.ijcard.2019.11.052

Back

Depression, Anxiety, Knowledge, Beliefs About Medication and Quality of Life Among Newly Anticoagulated Atrial Fibrillation Patients

Article 2019 en

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2018

Discontinuation risk comparison among ‘real-world’ newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban

Professor Gregory Lip, Xianying Pan, Shital Kamble, Hugh Kawabata, Jack Mardekian, Cristina Masseria, Hemant Phatak

Article2022

Life-Years Lost After Newly Diagnosed Atrial Fibrillation in Patients with Heart Failure

Nicklas Vinter, Pia Cordsen, Professor Gregory Lip, Emelia J. Benjamin, Søren Paaske Johnsen, Lars Frost, Ludovic Trinquart

Article2022

Hematuria in anticoagulated patients with atrial fibrillation and urologic cancer

Anne Gulbech Ording, Mette Søgaard, Flemming Skjøth, Erik Lerkevang Grove, Professor Gregory Lip, Torben Bjerregaard Larsen, Peter Brønnum Nielsen

Article2018

Effects of depression and anxiety on quality of life in five common neurological disorders

Joey C. Prisnie, Tolulope T. Sajobi, Meng Wang, Scott Burton Patten, Kirsten M. Fiest, Andrew G. M. Bulloch, Tamara Pringsheim, Samuel Wiebe, Nathalie Jetté

Article2021

Prediction of Residual Stroke Risk in Anticoagulated Patients with Atrial Fibrillation: mCARS

Wern Yew Ding, José Miguel Rivera‐Caravaca, Francisco Marı́n, Christian Torp‐Pedersen, Vanessa Roldán, Professor Gregory Lip